Drug Profile
Research programme: MCP-1 receptor antagonists - sanofi-aventis/Millennium
Alternative Names: CCR2 antagonists research programme - sanofi-aventis/Millennium; MCP-1 receptor antagonists research programme - sanofi-aventis/Millennium; Research programme: CCR2 antagonists - sanofi-aventis/MillenniumLatest Information Update: 19 Jul 2006
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals; sanofi-aventis
- Class Small molecules
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Rheumatoid arthritis
Most Recent Events
- 19 Jul 2006 No development reported - Preclinical for Rheumatoid arthritis in USA (PO)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 03 Feb 2004 No development reported - Preclinical for Atherosclerosis in USA (PO)